About Us
World Leaders in Biomarker and Bioanalysis Research Services
A thesis developed by Synexa, integrating discrete components to form a connected whole.
Insight into the biology of immunogenicity and its role in drug development.
About Us
World Leaders in Biomarker and Bioanalysis Research Services
A thesis developed by Synexa, integrating discrete components to form a connected whole.
NanoString nCounter Technology – COVID-19 Immunological and Inflammatory Response
About Us
World Leaders in Biomarker and Bioanalysis Research Services
A thesis developed by Synexa, integrating discrete components to form a connected whole.
Lack of implantation of an embryo: when the numbers count
About Us
World Leaders in Biomarker and Bioanalysis Research Services
A thesis developed by Synexa, integrating discrete components to form a connected whole.
SARS-CoV-2: when does the calm become the perfect storm?
Previous
Next
Biomarker & Bioanalytical expertise
Synexa Life Sciences has been providing expert insights for the clinical development of therapeutics for almost 20 years.
Biomarker Science
Insights that will improve the quality of decision-making through each stage of a therapeutic’s development.
Bioanalytical Science
Invaluable insight into the bioanalytical profile of large molecule therapeutics.
Research & Development
An expanding series of R&D programs that form the foundation for future services and products.
VECTORS
Vectors are objects which have both magnitude and direction.
Clinical Trials
The value of biomarkers
| biomarker science |
Biomarkers are the keystone of R&D productivity, creating value through:
Elucidation of Mechanism
Biomarkers provide indispensable reflections of a therapy’s mechanism of action in terms of safety, efficacy, and application.
Enriched patient populations
Biomarker-based stratification can be used to enrich patient populations to reduce trial size, duration, and cost.
Enhanced pipeline management
Biomarkers are critical tools in the prioritisation of products within a pipeline and the management of R&D capital allocation.
Expedited regulatory approval
Biomarker information is a key component of the “Totality of Evidence” required to push a compound over the evidentiary threshold for regulatory approval.
End-to-end biomarker analysis services
01
Global servicing capabilities
02
Discovery of new biomarkers
03
Method Development & Validation
04
Advising biomarker selection
05
Portfolio of validated assays
06
ProtoTrials™
07
Results interpretation and insight
